Nippon Shinyaku Co., Ltd. (NPPNY)
OTCMKTS
· Delayed Price · Currency is USD
6.50
0.00 (0.00%)
Apr 28, 2025, 4:00 PM EDT
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 41.99B JPY in the quarter ending December 31, 2024, with 6.53% growth. This brings the company's revenue in the last twelve months to 156.85B, up 6.71% year-over-year. In the fiscal year ending March 31, 2024, Nippon Shinyaku had annual revenue of 148.26B with 2.83% growth.
Revenue (ttm)
156.85B JPY
Revenue Growth
+6.71%
P/S Ratio
1.72
Revenue / Employee
70.88M JPY
Employees
2,213
Market Cap
1.72B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
Mar 31, 2020 | 116.64B | 1.92B | 1.67% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Nippon Shinyaku News
- 3 months ago - Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
- 3 months ago - REGENXBIO partners with Nippon Shinyaku for MPS therapies - Seeking Alpha
- 3 months ago - Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
- 7 months ago - Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha
- 8 months ago - Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - Seeking Alpha
- 8 months ago - EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga